Brightline-4: A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients With Treatment -na?ve or Pre-treated Advanced D

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Abhijeet Kumar
Sponsor
Boehringer Ingelheim Pharmaceuticals, Inc
Unit
Cancer Center Division